Publication

Article

February 16, 2021

Supplements and Featured Publications

Current and Emerging Trends in Chronic Myeloid Leukemia

Volume1

Issue 1

Current and Future Trends in Chronic Myeloid Leukemia

This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.

Download Issue PDF

Articles in this issue

chronic myeloid leukemia

Current and Future Trends in Chronic Myeloid Leukemia

Gabriela Hobbs, MD, of Massachusetts General Hospital

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

Jorge E. Cortes, MD, of the Georgia Cancer Center at Augusta University

Dr. Cortes on the Future of Ponatinib in CML Treatment

Kendra Sweet, MD, of Moffitt Cancer Center

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic lymphocytic leukemia.

Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CML

Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.

Dr. Hobbs on Choosing Optimal Second-Line Treatment Option for TKI-Resistant CLL

Jorge E. Cortes, MD, shares advice for navigating among first- and second-generation TKIs in the frontline treatment of patients with chronic myeloid leukemia.

Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigm

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CML

Gaby Hobbs, MD, of Massachusetts General Hospital

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

Kendra Sweet, MD, of Moffitt Cancer Center

Dr. Sweet on Treatment Selection With TKIs in CML

Related Videos

Howard S. Hochster, MD, FACP,

John H. Strickler, MD

Brandon G. Smaglo, MD, FACP

Cedric Pobel, MD

Ruth M. O’Regan, MD

Related Content

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center

November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Susana M. Campos, MD, MPH

November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Whitney Goldsberry, MD

November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester

November 20th 2024

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com

November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

FDA

November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Related Content

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center

November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Susana M. Campos, MD, MPH

November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Whitney Goldsberry, MD

November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester

November 20th 2024

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com

November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

FDA

November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.